Indications for: PAMELOR
Initially 25mg 3–4 times daily; max 150mg/day. Elderly and adolescents: 30–50mg/day in single or divided doses.
During or within 14 days of MAOIs. Concomitant linezolid or IV methylene blue. Acute post-MI.
Suicidality and antidepressant drugs.
Increased risk of suicidal thinking and behavior in children, adolescents and young adults; monitor for clinical worsening and unusual changes. Monitor for emergence of serotonin syndrome; discontinue if occurs. Mania/hypomania. Bipolar disorder. Psychosis. ECT. Cardiovascular disease. Avoid in Brugada syndrome. Angle-closure glaucoma. Urinary retention. Epilepsy. Hyperthyroidism. Diabetes. Liver disorders. Monitor plasma levels if dose >100mg/day. Elderly. Pregnancy. Nursing mothers.
See Contraindications. Increased risk of serotonin syndrome with other serotonergic drugs (eg, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue). Potentiates alcohol, sympathomimetics. CNS stimulation with reserpine. Potentiated by CYP2D6 inhibitors; monitor plasma levels with quinidine, cimetidine, SSRIs, phenothiazines, type 1C antiarrhythmics (eg, propafenone, flecainide). Antagonized by barbiturates, carbamazepine. Paralytic ileus, hyperpyrexia with anticholinergics. Blocks guanethidine.
Drowsiness, anticholinergic effects, CNS overstimulation, arrhythmias, extrapyramidal symptoms, hypo- or hypertension, nausea, fatigue, rash, headache, changes in blood sugar, photosensitivity, edema, blood dyscrasias, jaundice.
Caps—30; Soln—contact supplier